Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2003

View Archived Issues

T-614 stimulates bone formation in vitro and in vivo

Celecoxib with chemotherapy reported safe as palliative therapy for relapsed NHL

Good safety profile suggested for the antiangiogenic PI-88 in advanced solid cancer

Evidence of response found with 2-methoxyestradiol in solid tumors

Reduced tumorigenicity of prostate cancer cells found with contortrostatin

Three series of chemokine CCR5 receptor modulators and their use reported by AstraZeneca

GSK and Pliva researchers present new antibacterial macrolides in recent patent

Preclinical efficacy of a humanized anti-CD20 monoclonal antibody against NHL

Novel series of alpha7 nAChR agonists covered by Pharmacia patent

Boehringer Ingelheim claims new ITK inhibitors and their use in inflammation, cancer, allergy, etc.

Dual 5-HT1A agonists/dopamine D2 antagonists newly developed by Merck KGaA team

Novel glucocorticoid agonists in early development at GSK

Rutgers scientists identify novel topoisomerase inhibitors for cancer and other uses

Avant awarded two new subcontracts for oral anthrax and plague vaccines

Pennsaid launched in Italy

Genasense enters new combination trial in advanced breast cancer

3M submits sNDA for Aldara in superficial basal cell carcinoma

MDX-010 enters new phase I trial in HIV

Orathecin granted European orphan medical product status for pancreatic cancer

U.S. phase III trials of once-daily tramadol complete enrollment

FDA approval for Benicar HCT

Barr completes agreement to acquire Wyeth products

Preclinical data on oleoyl-estrone presented in Helsinki

Improved maintenance of vision reported with anecortave acetate in exudative AMD

Improved glycemic control found for liraglutide in obese patients with type 2 diabetes

A new clinical trial to evaluate Neovastat(R) in metastatic renal cell carcinoma

Stronger potency reported for ISA-247 vs. ciclosporin in renal transplant patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...